Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esomeprazole vs Omeprazole in Acute Non-Variceal Upper GI Bleeding
NCT00402259Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of esomeprazole in upper gastrointestinal bleeding (UGIB) (2 arms), sponsored by AstraZeneca. Primary endpoint: Proportion of subjects who present with no clinically significant bleeding after 5 days treatment. Started Aug 2006; status: completed.
02
Drugs
esomeprazole
03
Conditions
upper gastrointestinal bleeding (UGIB)
Beyond the preview
Go deeper on NCT00402259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00402259.